Force degradation studies of relugolix: identification, isolation and structure characterization of stress degradation products by using liquid chromatography-mass spectrometry, auto purification mass mediated preparative-high performance liquid chromatography, high resolution mass spectrometry, nuclear magnetic resonance spectroscopy

被引:0
作者
Pulletikurthi, K. V. K. Mohan [1 ,2 ]
Annapurna, Nowduri [2 ]
Doddipalla, Raju [1 ]
Vijay, Rajani [1 ]
Rumalla, Chidananda Swamy [1 ]
Kaliyaperumal, Muralidharan [1 ]
Rendedula, Deviprasad [1 ]
Kavitapu, Dasameswara Rao [1 ]
机构
[1] GVK Biosci Pvt Ltd, Dept Med Chem, Hyderabad, Telangana, India
[2] Andhra Univ, Dept Engn Chem, Visakhapatnam, Andhra Pradesh, India
关键词
Degradation products; high resolution mass spectrometry; liquid chromatography mass spectrometry; nuclear magnetic resonance spectroscopy; preparative-high performance liquid chromatography;
D O I
10.1080/00387010.2022.2029903
中图分类号
O433 [光谱学];
学科分类号
0703 ; 070302 ;
摘要
To assess the stability of Relugolix under stress conditions, identify and characterize the degradation products, it was subjected to hydrolytic and oxidative stress conditions, according to the International Council for Harmonization guideline Q1A (R2). The drug showed degradation in basic and oxidative conditions, while it was stable in acid conditions. Four degradation products were obtained, two from each basic and oxidative degradation, which was separated on a C18 column by using Auto Purification Mass Spectrometer. The four degradant products have not been reported earlier in any of the literature and are being reported here for the first time.
引用
收藏
页码:128 / 137
页数:10
相关论文
共 17 条
[1]  
[Anonymous], 2009, ANN 2 WHO TECHN REP, V953
[2]  
[Anonymous], 2005, Int. Conf. Harmon. Tech. Requir. Regist. Pharm. Hum. Use
[3]  
Baertschi S.W., 2011, PHARM STRESS TESTING, P19
[4]   Relugolix for the treatment of uterine fibroids [J].
Barra, F. ;
Seca, M. ;
Della Corte, L. ;
Giampaolino, P. ;
Ferrero, S. .
DRUGS OF TODAY, 2019, 55 (08) :503-512
[5]  
FDA, 2020, NEWS REL FDA APPR 1
[6]  
FDA, APPR DRUG PROD ORG R
[7]  
Huynh-Ba, 2009, HDB STABILITY TESTIN, P18
[8]  
I.C.H. Guideline, 2003, Stability testing of new drug substances and products Q1A(R2)
[9]  
ICH, 2003, Stability Testing of New Drug Substances and Products Q1A (R2)
[10]   Relugolix: First Global Approval [J].
Markham, Anthony .
DRUGS, 2019, 79 (06) :675-679